{
    "clinical_study": {
        "@rank": "92283", 
        "arm_group": {
            "arm_group_label": "SD-101 + Combined with Local Radiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Direct intratumoral injection of SD-101 with local radiation is safe in patients with\n      relapsed or refractory lymphoma after allogeneic hematopoietic cell transplant."
        }, 
        "brief_title": "Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)", 
        "condition": [
            "Lymphoma, Non-Hodgkin", 
            "Hodgkin Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will receive low dose radiation to all bulky or symptomatic lymph nodes on days -2\n      and -1. SD-101 will be administered intratumorally to the single largest palpable node\n      within 24 hours after completion of radiation, on day 0. Two additional intratumoral SD-101\n      injections will be performed on days 7 (+/- 2 days) and 14 (+/- 2 days). This is a dose\n      ranging study using a 3+3 design with a definition of maximum tolerated dose (MTD) which our\n      group has found acceptable in the past. The first cohort of patients will receive a SD-101\n      dose of 0.3 mg per injection. The dose will be escalated to 1 mg and 3 mg based on dose\n      limiting toxicity (DLT)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section\n             3.2.1 for excluded subtypes)\n\n          2. At least 3 sites of disease\n\n             i. One for diagnosis (lymph node or bone marrow biopsy)\n\n             ii. One palpable for treatment\n\n             iii. One measurable radiographically\n\n          3. > 60 days after RIC allogeneic transplant for lymphoma\n\n          4. 18 years of age or older\n\n          5. Mixed (5-95%) or complete (>95%) chimerism\n\n          6. Eastern Oncology Cooperative Group (ECOG) performance status \u2264 2\n\n          7. ANC >1000/mm3, platelets >50,000/mm3\n\n          8. Total bilirubin \u2264 2.5 mg/dL, AST and ALT < 3 times upper limit of normal\n\n          9. Serum creatinine \u2264 3 mg/dL\n\n         10. No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to\n             scheduled treatment\n\n         11. Minimal immunosuppression (defined as monotherapy with \u2264 10 mg prednisone daily, \u2264\n             200 mg cyclosporine daily, or \u2264 2 mg tacrolimus daily) at least 2 weeks prior to\n             scheduled treatment\n\n        Exclusion Criteria\n\n          1. HIV associated lymphoma\n\n          2. Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)\n\n          3. Active infection within 14 days prior to scheduled treatment\n\n          4. Active Cytomegalovirus (CMV) disease at the time of enrollment\n\n          5. Pre-existing autoimmune or antibody mediated disease (including systemic lupus\n             erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and\n             autoimmune thrombocytopenia)\n\n          6. Pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745354", 
            "org_study_id": "BMT235", 
            "secondary_id": [
                "SU-07212011-8129", 
                "20741"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "SD-101 + Combined with Local Radiation", 
                "description": "SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg", 
                "intervention_name": "SD-101", 
                "intervention_type": "Drug", 
                "other_name": "Dynavax"
            }, 
            {
                "arm_group_label": "SD-101 + Combined with Local Radiation", 
                "intervention_name": "Local Radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Physician Referrals", 
                "phone": "650-723-0822"
            }, 
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Edgar G Engleman", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Richard T Hoppe", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ronald Levy", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lauren Maeda", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Samuel Strober", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determination of the maximum tolerated dose based on dose limiting toxicity defined as any new grade 3-4 toxicity after the first SD-101 administration", 
            "safety_issue": "Yes", 
            "time_frame": "60 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745354"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Measure cytotoxic T-cell activity  changes pre- and post-treatment of tumor infiltrating lymphocytes and peripheral blood lymphocytes using ELISA and Immunohistochemistry.", 
                "safety_issue": "No", 
                "time_frame": "2, 3, 8 weeks after treatment"
            }, 
            {
                "measure": "Measure tumor response by PET-CT scan imaging", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "description": "Collect PBMCs", 
                "measure": "Measure level of donor specific tumor infiltrating lymphocytes by flow cytometry and Immunofluorescence", 
                "safety_issue": "No", 
                "time_frame": "2, 3, 8 weeks after treatment"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}